Literature DB >> 3950443

An in vitro investigation of the intracellular bioactivity of amoxicillin, clindamycin, and erythromycin for Staphylococcus aureus.

R Anderson, G Joone, C E van Rensburg.   

Abstract

The intraphagocytic bioactivities for Staphylococcus aureus of amoxicillin, clindamycin, and erythromycin (0.0075-20 micrograms/ml) were measured in human polymorphonuclear leukocytes (PMNLs) with the combination of a fluorochrome microassay and a radioassay. PMNLs with normal or depleted membrane-associated oxidative metabolism were used to investigate the interactions that may occur between the intrinsic O2-dependent antimicrobial systems of human phagocytes and antimicrobial agents in the elimination of intracellular microbial pathogens. Neutralization of O2-dependent antimicrobial systems with retention of phagocytic capacity was achieved with use of PMNLs from four children with chronic granulomatous disease (CGD) or NaF-pulsed normal PMNLs. None of the test antibiotics possessed intracellular bactericidal activity. Clindamycin and erythromycin possessed significant intracellular bacteriostatic activity relative to the modest activity of amoxicillin. Optimal intracellular bioactivity of all three antibiotics was obtained with normal PMNLs relative to NaF-pulsed or CGD PMNLs, a result indicating the existence of beneficial interactions between the antimicrobial agents and the O2-dependent antimicrobial systems of PMNLs.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3950443     DOI: 10.1093/infdis/153.3.593

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.

Authors:  José L Martínez; Fernando Baquero
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

2.  Effect of clavulanic acid and/or polymorphonuclear neutrophils on amoxicillin bactericidal activity against Streptococcus pneumoniae.

Authors:  M Martín; M L Gómez-Lus; L Aguilar; P Martínez; M J Giménez; J Prieto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-07       Impact factor: 3.267

Review 3.  Phagocyte uptake and transport of azithromycin.

Authors:  P J McDonald; H Pruul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 4.  Intracellular concentrations of antibacterial agents and related clinical implications.

Authors:  J D Butts
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

5.  Azithromycin enhances phagocytic killing of Aggregatibacter actinomycetemcomitans Y4 by human neutrophils.

Authors:  Pin-Chuang Lai; Mark R Schibler; John D Walters
Journal:  J Periodontol       Date:  2015-01       Impact factor: 6.993

6.  New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms.

Authors:  K Hultén; R Rigo; I Gustafsson; L Engstrand
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Reduction of wall degradability of clindamycin-treated staphylococci within macrophages.

Authors:  J Wecke; L Johannsen; P Giesbrecht
Journal:  Infect Immun       Date:  1990-01       Impact factor: 3.441

8.  In vitro and in vivo intraleukocytic accumulation of azithromycin (CP-62, 993) and its influence on ex vivo leukocyte chemiluminescence.

Authors:  M Bonnet; P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

Review 9.  Dirithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 10.  Intracellular Penetration and Effects of Antibiotics on Staphylococcus aureus Inside Human Neutrophils: A Comprehensive Review.

Authors:  Suzanne Bongers; Pien Hellebrekers; Luke P H Leenen; Leo Koenderman; Falco Hietbrink
Journal:  Antibiotics (Basel)       Date:  2019-05-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.